



2018/SEC/APRIL/313

April 6, 2018

To,  
The Manager Listing  
**The BSE Limited,**  
Corporate Service Department  
Floor 25, P J Towers,  
Dalal Street, Mumbai 400 001  
**Scrip Code: 539268**

To,  
The Manager Listing  
**The National Stock Exchange of India Limited**  
Corporate Communication Department  
Exchange Plaza, Bandra – Kurla Complex,  
Bandra (East), Mumbai- 400 051  
**Scrip Symbol: SYNGENE**

**Biocon Limited**  
20th KM Hosur Road  
Electronics City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423  
CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

To,  
**Syngene International Limited**  
Biocon Park SEZ, Bommasandra Industrial Area  
Phase IV Bommasandra, Jigani Link Road,  
Bengaluru-560099

**Sub: Annual Disclosure under Regulation 30(1) and 30(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011**


Dear Sir/Madam,

This is with reference to the disclosure required under Regulation 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("Takeover Regulations") regarding aggregate shareholding and voting rights held by the promoter(s), member of promoter group and PAC with them as of the March 31, 2018.

We are enclosing herewith the said disclosures as on March 31, 2018 relating to Syngene International Limited in the prescribed format.

Request to kindly take this intimation on record.

Yours faithfully,  
For **BIOCON LIMITED**

  
Authorised Signatory

**Enclosed:** Disclosure under regulation 30(1) & 30(2) of SEBI (SAST) Regulation, 2011

Email to

BSE: [corp.relations@bseindia.com](mailto:corp.relations@bseindia.com)

NSE: [takeover@nse.co.in](mailto:takeover@nse.co.in)

**ANNEXURE – 1**

**Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

**Part-A- Details of Shareholding**

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                    |                                                          |                                                   |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------|
| 1 | Name of the Target Company (TC)                                                                                                                                                                                                                                                                                                                                                                                                   | <b>Syngene International Limited</b>                                                                                                                                                                                                                                                                               |                                                          |                                                   |
| 2 | Name(s) of the stock exchange(s) where the shares of the TC are listed                                                                                                                                                                                                                                                                                                                                                            | 1. BSE Limited<br>2. National Stock Exchange of India Limited                                                                                                                                                                                                                                                      |                                                          |                                                   |
| 3 | Particulars of the shareholder(s) :<br><br>a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC.<br>OR<br>b. Name(s) of promoter(s), member of the promoter group and PAC with him. | <b>Promoter(s)</b><br>1. M/s. Biocon Limited<br><b>Promoter Group</b><br>2. M/s. Biocon Research Limited<br>3. M/s. Biocon Limited Employee Welfare Trust<br>4. Ms. Kiran Mazumdar Shaw<br>5. Ms. Yamini R Mazumdar<br>6. Mr. Dev Mazumdar<br>7. Prof. Ravi Rasendra Mazumdar & Prof. Catherine Patricia Rosenberg |                                                          |                                                   |
| 4 | Particulars of the shareholding of person(s) mentioned at (3) above                                                                                                                                                                                                                                                                                                                                                               | Number of shares                                                                                                                                                                                                                                                                                                   | % w.r.t. total share /voting capital wherever applicable | % of total diluted share/voting capital of TC (*) |
|   | As of March 31st, of the year, holding of:                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                    |                                                          |                                                   |
|   | a. Shares                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                    |                                                          |                                                   |
|   | 1. M/s. Biocon Limited                                                                                                                                                                                                                                                                                                                                                                                                            | 145,217,843                                                                                                                                                                                                                                                                                                        | 72.61%                                                   | 72.61%                                            |
|   | 2. M/s. Biocon Research Limited                                                                                                                                                                                                                                                                                                                                                                                                   | 1,866,673                                                                                                                                                                                                                                                                                                          | 0.93%                                                    | 0.93%                                             |
|   | 3. M/s. Biocon Limited Employee Welfare Trust                                                                                                                                                                                                                                                                                                                                                                                     | 1,789,897                                                                                                                                                                                                                                                                                                          | 0.90%                                                    | 0.90%                                             |
|   | 4. Ms. Kiran Mazumdar Shaw                                                                                                                                                                                                                                                                                                                                                                                                        | 7,638                                                                                                                                                                                                                                                                                                              | 0.00%                                                    | 0.00%                                             |
|   | 5. Ms. Yamini R Mazumdar                                                                                                                                                                                                                                                                                                                                                                                                          | 4,000                                                                                                                                                                                                                                                                                                              | 0.00%                                                    | 0.00%                                             |
|   | 6. Mr. Dev Mazumdar                                                                                                                                                                                                                                                                                                                                                                                                               | 3,500                                                                                                                                                                                                                                                                                                              | 0.00%                                                    | 0.00%                                             |
|   | 7. Prof. Ravi Rasendra Mazumdar & Prof. Catherine Patricia Rosenberg                                                                                                                                                                                                                                                                                                                                                              | 1,060                                                                                                                                                                                                                                                                                                              | 0.00%                                                    | 0.00%                                             |
|   | b. Voting Rights (otherwise than by shares)                                                                                                                                                                                                                                                                                                                                                                                       | NIL                                                                                                                                                                                                                                                                                                                | NIL                                                      | NIL                                               |
|   | c. Warrants,                                                                                                                                                                                                                                                                                                                                                                                                                      | NIL                                                                                                                                                                                                                                                                                                                | NIL                                                      | NIL                                               |
|   | d. Convertible Securities                                                                                                                                                                                                                                                                                                                                                                                                         | NIL                                                                                                                                                                                                                                                                                                                | NIL                                                      | NIL                                               |
|   | e. Any other instrument that would entitle the holder to receive shares in the TC.                                                                                                                                                                                                                                                                                                                                                | NIL                                                                                                                                                                                                                                                                                                                | NIL                                                      | NIL                                               |
|   | <b>Total</b>                                                                                                                                                                                                                                                                                                                                                                                                                      | <b>148,890,611</b>                                                                                                                                                                                                                                                                                                 | <b>74.45%</b>                                            | <b>74.45%</b>                                     |